Methods for identifying 30 chronic conditions: application to administrative data

Marcello Tonelli, Natasha Wiebe, Martin Fortin, Bruce Guthrie, Brenda R Hemmelgarn, Matthew T James, Scott W Klarenbach, Richard Lewanczuk, Braden J Manns, Paul Ronksley, Peter Sargious, Sharon Straus, Hude Quan and For the Alberta Kidney Disease Network

Abstract

Background: Multimorbidity is common and associated with poor clinical outcomes and high health care costs. Administrative data are a promising tool for studying the epidemiology of multimorbidity. Our goal was to derive and apply a new scheme for using administrative data to identify the presence of chronic conditions and multimorbidity.

Methods: We identified validated algorithms that use ICD-9 CM/ICD-10 data to ascertain the presence or absence of 40 morbidities. Algorithms with both positive predictive value and sensitivity $\geq 70\%$ were graded as "high validity"; those with positive predictive value $\geq 70\%$ and sensitivity $< 70\%$ were graded as "moderate validity". To show proof of concept, we applied identified algorithms with high to moderate validity to inpatient and outpatient claims and utilization data from 574,409 people residing in Edmonton, Canada during the 2008/2009 fiscal year.

Results: Of the 40 morbidities, we identified 30 that could be identified with high to moderate validity. Approximately one quarter of participants had identified multimorbidity (2 or more conditions), one quarter had a single identified morbidity and the remaining participants were not identified as having any of the 30 morbidities.

Conclusions: We identified a panel of 30 chronic conditions that can be identified from administrative data using validated algorithms, facilitating the study and surveillance of multimorbidity. We encourage other groups to use this scheme, to facilitate comparisons between settings and jurisdictions.

Keywords: Multimorbidity, Administrative data

Background

Management of chronic disease is the major challenge facing health systems worldwide [1]. Many people with chronic disease have multiple chronic conditions, which is termed multimorbidity [2]. It is clear that multimorbidity is common and associated with worse clinical outcomes and higher health care costs, compared to good health or to the presence of a single chronic condition [3-6]. However, there are key knowledge gaps concerning the basic epidemiology of multimorbidity [7]; its clinical and economic consequences; and how it contributes to disparities in health [8]. This information is prerequisite to mitigating the impact of multimorbidity and chronic disease [9].

Multimorbidity has been identified as a key research priority by the Public Health Agency of Canada, and is crucial to inform programming and resource forecasting. Knowledge of secular changes in the incidence and prevalence of multimorbidity is required, and would be facilitated by methods for identifying the presence of multimorbidity using administrative data.

Identifying morbidity using administrative data can be simple (e.g., based on a single hospitalization and using only a small number of codes) or complex (e.g., including inpatient and outpatient encounters and long lists of codes). Once developed, algorithms may be validated against a suitable gold standard (e.g., chart reviews; other previously validated algorithms).

Previous work by Barnett et al [3] identified 40 morbidities and were informed by a systematic review of multimorbidity measures [10], the Quality and Outcomes...
Framework of the UK General Practice contract, and health service planning by NHS Scotland. However, these authors used administrative data sources that are unique to the United Kingdom to identify the presence or absence of these conditions. A corresponding scheme based on the more widely used ICD-9 CM/ICD-10 system is not available.

Therefore, we first identified previously validated algorithms that use the ICD-9 CM/ICD-10 system for ascertaining the presence of chronic conditions using inpatient and outpatient claims and utilization data. We then showed proof of concept for using administrative data to study multimorbidity, by applying these previously validated algorithms to a population of adults residing in Edmonton, Canada between April 2008 and March 2009.

Methods

The institutional review boards at the University of Alberta (Pro00038795) and the University of Calgary (E22590) approved the study.

Morbidity

We did a focused literature search for validated algorithms that use ICD-9 CM/ICD-10 codes in administrative data from inpatient and outpatient encounters to ascertain the presence or absence of the 40 morbidities identified by Barnett et al [3]. We searched MEDLINE using combinations of the following MeSH subject headings together with the specific morbidity of interest: ‘International Classification of Diseases’, ‘Reproducibility of Results’, and ‘Sensitivity and Specificity’. Based on an a priori decision, we considered algorithms to be of high validity if they had both positive predictive value (PPV) and sensitivity ≥70% as compared to an acceptable gold standard such as chart review. We considered algorithms to be of moderate validity if they had PPV ≥70% but sensitivity <70%. The cut-off values for PPV and sensitivity were based on previous validation studies of administrative data [11]. We did not consider negative predictive value or specificity, because these parameters are generally >90% in studies of chronic diseases among the general population [11,12]. The definition of multimorbidity required the coexistence of two or more of the morbidities. In a secondary analysis we used a more restrictive definition that required three or more morbidities to be present.

ICD codes

Canadian hospital discharge abstract data are coded with ICD-10 CA, which essentially increases specificity compared to the ICD-10 system by adding more digits [11]. All of the ICD-10 codes from the included algorithms are consistent with ICD-10 CA codes, and thus we used ICD-10 and ICD-10 CA codes interchangeably throughout this manuscript. When ICD-10 codes were not given in the primary papers, we used the Canadian Institute for Health Information (CIHI; www.cihi.ca) conversion table to convert ICD-9 CM codes to ICD-10 codes. Many algorithms required multiple codes within a specified time period to determine incidence of morbidity (Table 1). In each case the index date for the disease was considered to be the date of the first code. For example, in order to determine presence of asthma, we searched for ICD-9 CM 493 and ICD-10 J45 codes in hospitalizations and outpatient encounters. We considered asthma to have developed at the first instance of a single hospitalization with either of these codes, or a single outpatient encounter followed by two further outpatient encounters with either of these codes within two years. In either case, we considered the participant to have asthma for the duration of follow-up.

Proof of concept

We applied identified algorithms with high or moderate validity to a population-based administrative dataset from Alberta Health (AH; the provincial health ministry) and Alberta clinical laboratories. Details of this administrative dataset including claims, hospitalizations and Ambulatory Care Classification System (ACCS) utilization are given in Figure 1 and have been reported elsewhere [13]. We assembled a cohort of adults aged ≥18 years who resided in the city of Edmonton, Alberta between April 2008 and March 2009, and included all people registered with AH. All Alberta residents are eligible for insurance coverage by AH, and ≥99% participate in this coverage. The dataset included demographic information such as postal code of residence, laboratory data, and medication in those aged ≥65 years [13]. We identified Edmonton residents from the AH registry file using the community name variable from the Statistics Canada Postal Code 2008 Conversion file [14] (www.statcan.gc.ca).

To demonstrate proof of concept for applying these algorithms to a large administrative dataset, we presented a simple summary of the prevalence of morbidity and multimorbidity in the study population. Counts and percentages were presented along with a figure showing how the number of morbidities varies by age. In sensitivity analyses, we presented the prevalence of morbidity as assessed by different sources of administrative data.

Results

Algorithms

We identified 16 morbidities for which the best identified algorithm was of high validity: asthma, atrial fibrillation, metastatic cancer, chronic heart failure, chronic kidney disease, chronic pain, cirrhosis, diabetes, hypertension, irritable bowel syndrome, multiple sclerosis, myocardial infarction, peripheral vascular disease, psoriasis, schizophrenia and...
| Morbidity                        | Algorithm                                                                 | Number and nature of claims required to substantiate the diagnosis | ICD-9 CM | ICD-10 | Permanent | Citation            |
|---------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------|----------|--------|-----------|---------------------|
|                                 |                                                                           | Hospitalizations | Claims | ACCS | Years | ICD-9 CM | ICD-10 |          |                      |
| Alcohol misuse                  | 1 hospitalization or 2 claims in 2 years or less                          | 1                  | 2      | .    | 2      | 265.2, 291.1–291.3, 291.5–291.9, 303.0, 303.9, 305.0, 357.5, 425.5, 535.3, 571.0–571.3, 980, V11.3 | E52, F10, G62.1, I42.6,K29.2, K70.0, K70.3, K70.9, T51, Z50.2, Z71.4, Z72.1 | Y Quan 2008 [11], 2005 [17] |
|                                |                                                                           | 1                  | .      | 3    | 2      | 493 | J45 | Y Gershon 2009 [37] |
| Asthma                          | 1 hospitalization or 3 ACCS in 2 years or less                            | 1                  | 2      | .    | 2      | 427.3 | I48.0 | Y Alonso 2009 [38] |
| Atrial fibrillation             | 1 hospitalization or 2 claims in 2 years or less                          | 1                  | 2      | .    | 2      | 200–202, 203.0, 238.6 | C81–C85, C88, C90.0, C90.2, C96 | N 5 y Quan 2008 [11], 2005 [17] |
|                                |                                                                           | 1                  | 2      | .    | 2      | 196–199 | C77–C80 | N 5 y Quan 2008 [11], 2005 [17] |
| Cancer, lymphoma                | 1 hospitalization or 2 claims in 2 years or less                          | 1                  | 2      | .    | 2      | 153-154, 162-163, 174, 180, 185, 230.3-230.6, 231.2, 233.0-233.1, 233.4 | C18–C21, C33–C34, C38.4, C45.0, C46.71, C50, C53, C61, D01.0-D01.3, D02.2, D05-D06, D07.5 | N 5 y Penberthy 2003 [39] |
| Cancer, metastatic              | 1 hospitalization or 2 claims in 2 years or less                          | 1                  | 2      | .    | 2      | 200–202, 203.0, 238.6 | C81–C85, C88, C90.0, C90.2, C96 | N 5 y Quan 2008 [11], 2005 [17] |
| Cancer, non-metastatic (breast, cervical, colorectal, lung, prostate) | 1 hospitalization or 2 claims in 2 years or less                          | 1                  | 2      | .    | 2      | 196–199 | C77–C80 | N 5 y Quan 2008 [11], 2005 [17] |
| Chronic heart failure$^\dagger$  | 1 hospitalization or 2 claims in 2 years or less                          | 1                  | 2      | .    | 2      | 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 425.4–425.9, 428 | I09.9, I25.5, I42.0, I42.5–I42.9, I43, I50 | Y Quan 2008 [11], 2005 [17] |
| Chronic kidney disease          | Mean eGFR < 60 mL/min*1.73 m$^2$ or mean albuminuria > 30 mg/g over 12 months | .                  | .      | .    | .      | . | Stevens 2013 [16] |
|                                | or 1 hospitalization or 3 claims in 1 year                               | 1                  | 3      | .    | 1      | 583, 584, 585, 586, 592, 593.9 | N00-N23 | Y Ronksley 2012 [15] |
| Chronic pain                    | 2 hospitalizations or 2 claims or 2 ACCS in 30 days or less               | 2                  | 2      | 2    | 30 d   | 307.80, 307.89, 338.0, 338.2, 338.4, 719.41, 719.45 - 719.47, 719.49, 720.0, 720.2, 720.9, 721.0 - 721.4, 721.6, 721.8, 721.9, 722, 723.0, 723.1, 723.3 - 723.9, 724.0 - 724.6, 724.70, 724.79, 724.8, 724.9, 729.0 - 729.2, 729.4, 729.5 | F45.4, M08.1, M25.50, M25.51, M25.55 - M25.57, M43.2 - M43.6, M45, M46.1, M46.3, M46.4, M46.9, M47, M48.0, M48.1, M48.8, M48.9, M50.8, M50.9, M51, M53.1 - M53.3, M53.8, M53.9, M54, M60.8, M60.9, M63.3, M79.0 - M79.2, M79.6, M79.7, M96.1 | N 2 y Tian 2013 [18] |
| Chronic pulmonary disease$^\ddagger$ | 1 hospitalization or 2 claims in 2 years or less                         | 1                  | 2      | .    | 2      | 416.8, 416.9, 490–492, 494-505, 506.4, 508.1, 508.8 | J27.8, J27.9, J40–J44, J46–J47, J60–J67, J68.4, J70.1, J70.3 | Y Quan 2008 [11], 2005 [17] |
| Morbidity                                      | Algorithm                                                                 | Code Numbers | Years | References               |
|-----------------------------------------------|---------------------------------------------------------------------------|--------------|-------|--------------------------|
| Chronic viral hepatitis B                     | 2 hospitalizations or 2 claims or 2 ACCS                                   | 2            | 2     | 6 mo                     | 70.2-70.3     | B16, B18.0-B18.1  | Y | Mahajan 2013 [40] |
| Cirrhosis^                                     | 1 hospitalization or 1 claim or 1 ACCS                                    | 1            | 1     |                          | 571.2, 571.5, 571.6 | K70.3, K74.3, K74.4, K74.5, K74.6 | Y | Goldberg 2012 [41] |
| and hepatic decompensation                    | 1 hospitalization or 1 claim or 1 ACCS                                    | 1            | 1     |                          | 456.0, 456.1, 456.20, 456.21, 567.0, 567.2, 567.21, 567.29, 567.8, 567.9, 572.2, 572.4, 789.5 | Y | Mahajan 2013 [40] |
|                                              |                                                                           |              |       |                          | Exclude 567.81, 567.82, 789.51 |              |               |               |
| Dementia^                                      | 1 hospitalization or 2 claims in 2 years or less                          | 1            | 2     | 2                        | 290, 294.1, 331.2 | F00–F03, F05.1, G30, G31.1 | Y | Quan 2008 [11], 2005 [17] |
| Depression^                                    | 1 hospitalization or 2 claims in 2 years or less                          | 1            | 2     | 2                        | 296.2, 296.3, 296.5, 300.4, 309, 311 | F204, F313–F315.5, F32, F33, F34.1, F41.2, F43.2 | N 2 y | Quan 2008 [11], 2005 [17] |
| Diabetes                                       | 1 hospitalization or 2 claims in 2 years or less                          | 1            | 2     | 2                        | 250              | E10-E14        | Y | Hux 2005 [42] |
| Epilepsy                                       | 1 most responsible hospitalization or 2 claims in 2 years or less or 1 most responsible ACCS | 1            | 2     | 1                        | 345              | G40-G41        | Y | Jette 2010 [43] |
| Hypertension^                                  | 1 hospitalization or 2 claims in 2 years or less                          | 1            | 2     | 2                        | 401-405         | I10-I13, I15   | Y | Quan 2009 [44] |
| Hypothyroidism                                 | 1 hospitalization or 2 claims in 2 years or less                          | 1            | 2     | 2                        | 240.9, 243, 244, 246.1, 246.8 | E00–E03, E89.0 | Y | Quan 2008 [11], 2005 [17] |
| Inflammatory bowel disease                    | 2 hospitalizations or 2 GAST or GP claims in 3 years or less              | 2            | 2     | 3                        | 555, 556        | K50, K51       | Y | Liu 2009 [19] |
| Irritable bowel syndrome                      | 1 hospitalization without surgery or 2 claims in 2 years or less          | 1            | 2     | 2                        | 564.1           | K58            | Y | Sands 2006 [21] |
| Multiple sclerosis                             | 2 hospitalizations or 2 claims in 3 years or less                          | 2            | 2     | 3                        | 323, 340, 341.0, 341.9, 377.3 | G35, G36, G37, H46 | Y | Marrie 2013 [20] |
| Myocardial infarction                          | 1 hospitalization                                                          | 1            |      |                          | 410              | I21-I22        | Y | Austin 2002 [45] |
| Parkinson’s disease                            | 1 hospitalizations or 1 claim                                             | 1            |      |                          | 332              | G20, G21, G22  | Y | Noyes 2007 [46] |
| Peptic ulcer disease                           | 1 hospitalization or 2 claims in 2 years or less                          | 1            | 2     | 2                        | 531.7, 531.9, 532.7, 532.9, 533.7, 533.9, 534.7, 534.9 | K25.7, K25.9, K26.7, K26.9, K27.7, K27.9, K28.7, K28.9 | N 2 y | Quan 2008 [11], 2005 [17] |
| Condition                                | 1 hospitalization or 1 claim or 1 ACCS | 1 | 1 | . | . | 440.2 | 470.2 | Y | Fan 2013 [47] |
|----------------------------------------|--------------------------------------|---|---|---|---|-------|-------|---|----------------|
| Peripheral vascular disease            |                                       | 1 | 1 | . | . | 696.1 | L40.0 - L40.4, L40.8, L40.9 | Y | Asgari 2013 [48] |
| Psoriasis                              |                                       | 1 | 1 | . | . | 446.5, 710.0–710.4, 714.0–714.2, 714.8, 725 | M05, M06, M31.5, M32–M34, M35.1, M35.3, M36.0 | Y | Quan 2008 [11], 2005 [17] |
| Rheumatoid arthritis                   |                                       | 1 | 2 | . | 2 | 295   | F20, F21, F23.2, F25 | Y | Lurie 1992 [49], Moscovice 1989 [50] |
| Schizophrenia                         |                                       | 1 | 2 | . | 2 | 560.1, 560.30, 560.39, 560.9, 564.0, 569.3, 569.89, K55.8, K56.0, K56.4, K56.7, K59.0, K63.1, K63.4, K63.81, K63.88, K92.80, K92.88 | N 2 y | Sands 2006 [21] |
| Severe constipation                    |                                       | 1 | 2 | . | 2 | Exclude 152-154, 158, 179-189, 197.5-197.6, 235.2, 239.0, 555-556, 568.0, 614.6, (560.9 if 789.01, 789.02, 789.06), and any CCPx surgery* listed in claims | Exclude C17-C21, C45.1, C48, C51-C58, C60-C68, C78.5-C78.6, D01.7, D01.9, D37.1-D37.5, K50-K51, K66.0, N73.6, N99.4 (K56.6 if R10.1), and any CCPx surgery* listed in claims | Y | Kokotailo 2005 [51] |
| Stroke or TIA                          |                                       | 1 | 1 | 1 | . | 362.3, 430, 431, 433.x1, 434.x1, 435, 436 | G45.0-G45.3, G45.8-G45.9, H34.1, I60, I61, I63, I64 | |

ACCS ambulatory care classification system, ICD-9 CM International Classification of Diseases 9th Revision Clinical Modification, ICD-10 International Classification of Diseases 10th Revision, CCPx Canadian Classification of Procedures, eGFR estimated glomerular filtration rate, GAST gastroenterologist, GP general practitioner, DERM dermatologist, ED emergency department, TIA transient ischemic attack.

Any diagnosis field was considered in the algorithms except when the original text specified otherwise. The index date for disease was set as the date for the first relevant claim. Diseases denoted as “permanent” were assumed to be present continuously from the index date; diseases that are not “permanent” were considered to remit if no claims were present for a specified period of time.

*The author did not intend 567.2 to generalize and include 567.22 or 567.23

#CCPx surgery codes in claims were included as exclusions for hospitalizations for severe constipation.

In claims the specific ICD-9 CM code for atrial fibrillation was not in use and so the less specific code 427.3 (which includes atrial flutter) was used in place of 427.31.

“The ICD-9 CM code 493 and the ICD-10 code J45 was removed from the chronic pulmonary disease algorithm as it was also included in the asthma algorithm.

$The ICD-10 codes I11 and I12 were eliminated from chronic heart failure as separate codes for heart failure are required.

^A number of codes were legitimately used in more than one algorithm: alcohol misuse and chronic heart failure (425.5, I42.6), alcohol misuse and cirrhosis (571.2, K70.3), chronic heart failure and hypertension (402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93), and depression and schizophrenia (F20.4).
severe constipation. We identified an additional 14 morbidities (including two algorithms for other types of cancer and one algorithm for another type of liver disease) for which the best identified algorithm was of moderate validity: alcohol misuse, lymphoma, non-metastatic cancer (breast, cervical, colorectal, lung, and prostate), chronic pulmonary disease, chronic viral hepatitis B, dementia, depression, epilepsy, hypothyroidism, inflammatory bowel disease, Parkinson’s disease, peptic ulcer disease, rheumatoid arthritis, and stroke or transient ischemic attack. We excluded the remaining morbidities for which no suitable algorithm could be identified (Additional file 1 Table S1).

Thus we identified 30 conditions using administrative algorithms (including ICD-9 CM and ICD-10 codes) that are summarized in the Table 1. Of these 30 algorithms, half were validated for both ICD-9 CM and ICD-10 codes.

We identified all conditions exclusively using ICD-9 CM and ICD-10 data with the exception of chronic kidney disease, for which we used a validated algorithm applied to ICD-9 CM and ICD-10 data [15] and supplemented using serum creatinine and albuminuria data [16]. We considered chronic kidney disease to be present if a participant met either the administrative or laboratory criteria.

In some cases, we made minor changes to the published algorithms to improve anticipated diagnostic performance, to increase consistency between algorithms used for the different conditions, and to include application to the outpatient setting. First, the original publications by Quan et al [11,17] required one hospitalization to identify the presence of a chronic condition; based on input from the first author of that paper, we modified this algorithm to allow either one inpatient code or two outpatient codes within two years to define the presence of these conditions. Second, to improve mapping of ICD-9 codes from the original (published) algorithm into ICD-10, we combined the ‘highly likely’ and the ‘likely’ codes from the original algorithm for chronic pain [18]. Third, for consistency, we modified algorithms that defined conditions as present if participants had two codes within any duration of follow-up (no matter how long) to require that the two codes occur within a three year period [19,20]. Fourth, we expanded the criteria for presence of atrial fibrillation, epilepsy, irritable bowel syndrome, and severe constipation to include two outpatient codes within two years for these conditions. However, to ensure that secondary (post-surgical) bowel complications were not incorrectly classified as chronic bowel conditions, we excluded any hospitalization for surgery when assessing the presence or absence of these conditions [21]. Fifth, we expanded the criteria for presence of stroke or TIA to include one outpatient code. Sixth, we reviewed all algorithms for overlapping codes (situations where the same code was
used to identify more than one condition), and modified
the algorithms to avoid double-counting of morbidities
(see footnotes in the Table 1 for specific details).

**Application of the algorithms to the Edmonton cohort**
The study cohort included 574,409 participants (Figure 1,
Table 2). Almost two-thirds were less than 50 years of age.
Ten percent were 70 years of age or older and the propor-
tion of men and women was similar. Approximately half
of all participants were not identified as having any of the
30 morbidities for which high or moderate validity algo-
rithms existed. Approximately one quarter were identified
as having one of these 30 morbidities. Another quarter
were identified as having 2 or more of these 30 morbid-
ities (meeting the primary criterion for multimorbidity),
whereas 12% had three or more (meeting the secondary
criterion for multimorbidity).

The apparent prevalence of most morbidities was greatly
reduced (often by 50% or more) when we assessed their
presence or absence using hospitalization data only
(Table 2). The addition of ACCS data to hospitalization
and claims data made little difference to prevalence esti-
mates, with the possible exceptions of chronic pain, hepa-
titis B and cirrhosis (the prevalences of which all changed
by >20%). In most cases, the algorithms as originally vali-
dated resulted in a prevalence that was intermediate be-
tween the most inclusive approach (using hospitalization,
claims and ACCS data) and the most restrictive approach
(using hospitalization data only). As expected, adding gold
standard laboratory data for kidney function (eGFR and
albuminuria) resulted in substantial increases in the appar-
ent prevalence of chronic kidney disease as compared to
administrative data alone, regardless of which administra-
tive data sources were used.

Figure 2 depicts the percentage of participants with
multimorbidity by age group. After hypertension (a preva-
ience of 23%), 21% had chronic kidney disease, 9% had
diabetes, and 9% had depression.

**Discussion**
From a published list of chronic conditions [3], we iden-
tified a total of 30 validated algorithms including 3 algo-
rithms for different types of cancer and 2 algorithms for
liver disease. We applied the algorithms to ICD codes
from claims and utilization data, and identified the pres-
ence or absence of these conditions in a cohort of 574,409
adults residing in Edmonton, Alberta between April 2008
and March 2009 (Figure 1). The overall prevalence of mul-
timorbidity in this cohort was 26%, which is similar to the
prevalence as reported in the Barnett study [3]. Our find-
ings demonstrate proof of concept for using administrative
data as a surveillance tool for multimorbidity in settings
with systems for reliably capturing population-based claims
and utilization data.

Multiple prior studies have ascertained the presence of
various chronic conditions in the context of assessing
multimorbidity [4,7,22-34]. Although there is no univer-
sally accepted definition of multimorbidity (or a list of
conditions that should be used to assess the presence of
multimorbidity) there appears to be consensus on several
issues. First, health conditions used to define multimor-
bidity should be chronic but not necessarily permanent.
Second, two or more concomitant conditions should be
required to identify a person as having multimorbidity.
Third, an attempt should be made to standardize defini-
tions across studies to facilitate comparisons between
populations [7,9,34,35]. At the same time, it is important
that algorithms selected for use with administrative data
should be validated against a gold standard – and demon-
strate acceptable diagnostic properties so as to ensure rea-
sonably accurate classification of individuals with respect
to morbidity status. We focused on validated algorithms
with positive predictive value and sensitivity ≥70%, com-
pared to an acceptable gold standard such as chart review.
Because we had access to laboratory data allowing a gold
standard assessment of kidney function, we primarily
assessed the presence of chronic kidney disease using esti-
mated glomerular filtration rate (eGFR) and albuminuria
rather than administrative data.

To our knowledge, this is the most comprehensive
panel of validated algorithms yet applied to administra-
tive data for the study of multimorbidity. Other studies
have used reasonable but unvalidated algorithms, a more
limited list of candidate chronic conditions or both. Al-
though there are undoubtedly other chronic conditions
that could be identified using administrative data, we fo-
cused on those for which available algorithms appear to
have adequate sensitivity as well as positive predictive
value. We will use the set of algorithms described herein
as the foundation for a series of studies describing the
epidemiology of multimorbidity in Alberta, Canada.

Besides the various definitions of multimorbidity that
they have used, existing studies in this area have several
other limitations [36]. First, population-based studies are
rare (especially in Canadian settings); most studies have
captured patients followed by a particular centre and are
vulnerable to referral bias. Second, most studies have
been unable to assess the link between multimorbidity
and clinical outcomes in subgroups defined by age, sex,
or low socioeconomic status. Third, little is known about
the relative frequency of individual chronic conditions
within the multimorbidity syndrome – or about which
clusters of conditions are most common and/or clinic-
ally significant. Fourth, studies examining the economic
consequences of multimorbidity have typically used rela-
atively unsophisticated methods and/or studied only select
populations. The scheme outlined in the current manu-
script will allow our group to do future studies that close
Table 2 Morbidity characteristics of participants residing in Edmonton, Alberta during the April 2008 to March 2009 fiscal year

| Characteristic | Prevalence, % | Final algorithm | Using hospitalizations, claims, and ACCS | Using only hospitalizations and claims | Using only hospitalizations and ACCS | Using only hospitalizations |
|----------------|---------------|----------------|-----------------------------------------|---------------------------------------|---------------------------------------|---------------------------|
| **Number of morbidities** |               |                |                                         |                                       |                                       |                           |
| One            | 23.3          | 24.0           | 23.9                                    | 12.0                                  | 6.9                                   |                           |
| Two            | 11.5          | 12.1           | 11.9                                    | 4.9                                   | 3.7                                   |                           |
| Three          | 5.6           | 6.0            | 5.8                                    | 2.5                                   | 2.1                                   |                           |
| Four           | 2.8           | 3.1            | 2.9                                    | 1.4                                   | 1.1                                   |                           |
| Five or more   | 3.4           | 3.7            | 3.4                                    | 1.8                                   | 1.4                                   |                           |
| **Morbidity**  |               |                |                                         |                                       |                                       |                           |
| Alcohol misuse | 2.4           | 2.8            | 2.4                                    | 2.4                                   | 1.8<sup>b</sup>                       |                           |
| Asthma         | 2.3           | 6.9            | 6.8                                    | 2.3<sup>b</sup>                       | 2.0<sup>b</sup>                       |                           |
| Atrial fibrillation | 2.4         | 2.5            | 2.4                                    | 1.9                                   | 1.6<sup>a</sup>                       |                           |
| Cancer, lymphoma | 0.2         | 0.2            | 0.2                                    | 0.1<sup>a</sup>                       | 0.1<sup>a</sup>                       |                           |
| Cancer, metastatic | 0.6         | 0.6            | 0.6                                    | 0.5                                   | 0.5                                   |                           |
| Cancer, non-metastatic | 2.2       | 2.2            | 2.2                                    | 1.1<sup>b</sup>                       | 1.0<sup>b</sup>                       |                           |
| Chronic heart failure | 2.5       | 2.6            | 2.5                                    | 1.6<sup>a</sup>                       | 1.4<sup>a</sup>                       |                           |
| Chronic kidney disease | 20.8      | 3.8 (20.9)     | 3.6 (20.8)                             | 2.9 (20.4)                            | 2.2 (20.1)<sup>a</sup>                |                           |
| Chronic pain   | 6.5           | 6.5            | 5.2                                    | 1.4<sup>b</sup>                       | 0.1<sup>b</sup>                       |                           |
| Chronic pulmonary disease | 7.0       | 7.2            | 7.0                                    | 2.7<sup>b</sup>                       | 2.3<sup>b</sup>                       |                           |
| Chronic viral hepatitis B | 0.1  | 0.1            | 0.1                                    | 0.1<sup>b</sup>                       | <0.1<sup>b</sup>                      |                           |
| Cirrhosis      | 0.2           | 0.2            | 0.1                                    | 0.1                                   | 0.1<sup>a</sup>                       |                           |
| Dementia       | 1.6           | 1.6            | 1.6                                    | 1.6<sup>a</sup>                       | 0.9<sup>a</sup>                       |                           |
| Depression     | 8.7           | 8.9            | 8.7                                    | 1.7<sup>b</sup>                       | 1.0<sup>b</sup>                       |                           |
| Diabetes       | 8.8           | 8.9            | 8.8                                    | 5.6<sup>b</sup>                       | 3.1<sup>b</sup>                       |                           |
| Epilepsy       | 1.4           | 1.4            | 1.2                                    | 0.7<sup>b</sup>                       | 0.1<sup>b</sup>                       |                           |
| Hypertension   | 22.8          | 23.0           | 22.8                                   | 8.8<sup>g</sup>                       | 7.8<sup>g</sup>                       |                           |
| Hypothyroidism | 7.6           | 7.6            | 7.6                                    | 2.3<sup>b</sup>                       | 2.2<sup>b</sup>                       |                           |
| Inflammatory bowel disease | 1.0  | 1.1            | 1.0                                    | 0.7<sup>a</sup>                       | 0.2<sup>b</sup>                       |                           |
| Irritable bowel syndrome | 1.9      | 2.0            | 1.9                                    | 0.6<sup>b</sup>                       | 0.4<sup>b</sup>                       |                           |
| Multiple sclerosis | 0.7        | 0.8            | 0.7                                    | 0.4<sup>a</sup>                       | 0.1<sup>b</sup>                       |                           |
| Myocardial infarction | 1.7      | -              | -                                      | -                                     | 1.7                                   |                           |
| Parkinson's disease | 0.5        | 0.5            | 0.5                                    | 0.3<sup>b</sup>                       | 0.2<sup>b</sup>                       |                           |
| Peptic ulcer disease | 0.2       | 0.2            | 0.2                                    | 0.1<sup>a</sup>                       | 0.1<sup>b</sup>                       |                           |
| Peripheral vascular disease | 0.7    | 0.7            | 0.6                                    | 0.3<sup>b</sup>                       | 0.2<sup>b</sup>                       |                           |
| Psoriasis      | 0.9           | 1.0            | 0.9                                    | 0.2<sup>b</sup>                       | 0.1<sup>b</sup>                       |                           |
| Rheumatoid arthritis | 1.5        | 1.6            | 1.5                                    | 0.8<sup>a</sup>                       | 0.5<sup>a</sup>                       |                           |
| Schizophrenia  | 1.5           | 1.5            | 1.5                                    | 0.7<sup>b</sup>                       | 0.6<sup>b</sup>                       |                           |
| Severe constipation | 0.6        | 0.7            | 0.6                                    | 0.4<sup>a</sup>                       | 0.3<sup>b</sup>                       |                           |
| Stroke or transient ischemic attack | 4.2   | 4.2            | 3.8                                    | 2.4<sup>a</sup>                       | 0.9<sup>d</sup>                       |                           |

<sup>a</sup>Indicate morbidities where removing a sources or sources resulted in prevalence reduced between 25 to 50% compared to estimates using all three sources.

<sup>b</sup>Demonstrates morbidities where prevalence was reduced >50% compared to all three sources.

The prevalence values in the first column and the bold prevalence values in the remaining columns are estimates from the final algorithms given in Table 1. The bolded prevalence values indicate which administrative datasets were used in the final algorithms.

<sup>1</sup>Values in brackets include laboratory data (estimated glomerular filtration rate and albuminuria) as gold standard measures of kidney function.
these knowledge gaps—informing policy and practice. We are optimistic that the scheme will also be used by other researchers from other jurisdictions with similar datasets—facilitating comparisons between studies. Future studies should test the relative importance of the morbidities identified in the current manuscript, as well as considering other potentially important morbidities for inclusion.

Limitations of the current approach include those common to all studies using administrative data. For example, we do not have information on potential confounders related to lifestyle (e.g., diet, smoking, exercise) or on measured blood pressure, which may be confounders when examining the association between multimorbidity and outcomes or costs. However, this limitation would not be expected to affect feasibility of applying the algorithms or the prevalence estimates reported here. Second, identification of some of the chronic conditions we studied might have been enhanced by simultaneous consideration of medication data [3]. We decided against including publicly funded medication data to define these conditions because medication coverage in Alberta is limited to people aged ≥65 years; those of lower SES; or with high annual medication costs. Thus, using medication data to define conditions would have biased towards a higher incidence of multimorbidity in older, poorer and sicker participants. We decided against restricting the cohort to people aged ≥65 years, because multimorbidity is relatively common in younger participants—and there might be important differences in the nature and implications of multimorbidity by age. Therefore, we will include all adult Albertans in our forthcoming analyses. Third, since participants must use medical services to be diagnosed with chronic conditions, our findings underestimate the true population burden of multimorbidity—especially for conditions that are less likely to lead to hospitalization but which may still significantly impact quality of life and other important outcomes. Fourth, we did not identify appropriate algorithms for all of the 40 target conditions, possibly because our searches were not exhaustive, and other important conditions such as obesity were not considered in this study. Therefore, our results likely underestimate the true prevalence of multimorbidity. Finally, although we focused on validated algorithms, the diagnostic performance of algorithms may vary between settings, based on coding practices and the reliability of data capture—and we did not systematically evaluate the quality of the original studies. Therefore (despite the lack of an *a priori* reason to suspect worse performance in our dataset), it is possible that some algorithms that were of high or moderate validity in other jurisdictions may perform less well when applied to Alberta data, especially with the modifications as described herein.

Conclusions
In summary, we identified a panel of 30 chronic conditions that can be identified from administrative data using validated algorithms, facilitating the study and surveillance of multimorbidity. We encourage other groups to use this scheme, to facilitate comparisons of data on multimorbidity between settings and jurisdictions.

Additional file

Additional file 1: Table S1. Validated algorithms for the original 40 morbidities.

Competing interests
There are no competing interests. This study is based in part by data provided by Alberta Health and Alberta Health Services. The interpretation and conclusions are those of the researchers and do not represent the views of the Government of Alberta. None of the study sponsors had a role in the study design; collection, analysis, and interpretation of data; writing the report; or in the decision to submit the report for publication.

Authors’ contributions
MT conceived the study. MT, NW and HQ designed and drafted the manuscript. NW performed the statistical analyses. All authors have made substantial contributions to the development of the manuscript, and have all been involved in revising it for important intellectual content and approved the final version.

Acknowledgments
The authors of this report are grateful to Ghenette Houston for administrative support, and to Sophanny Tiv for database development. This work was supported by the Canadian Institutes for Health Research (MOP 133582), by a team grant to the Interdisciplinary Chronic Disease Collaboration from the Alberta Heritage Foundation for Medical Research (AHFMR) and a Leaders Opportunity Fund grant from the Canada Foundation for Innovation. MT, HQ, and SK are supported by career salary awards from the Alberta Heritage Foundation for Medical Research (MOP 133582), by a team grant to the Interdisciplinary Chronic Disease Collaboration from the Alberta Heritage Foundation for Medical Research (AHFMR) and a Leaders Opportunity Fund grant from the Canada Foundation for Innovation. MT, HQ, and SK are supported by career salary awards from Alberta Innovates-Health Solutions. PR is supported by a post-doctoral fellowship award from the Canadian Institutes for Health Research.

Author details
1Department of Medicine, University of Calgary, Calgary, Canada.
2Department of Medicine, University of Alberta, Edmonton, Canada.
3Department of Family Medicine, Université de Sherbrooke, Sherbrooke, Canada.
4Population Health Sciences Division, Medical Research Institute, University of Dundee, Dundee, UK.
5Alberta Health Services, Edmonton,
References

1. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, et al. Priority actions for the non-communicable disease crisis. Lancet. 2011;377(9775):1438–47.
2. Fortin M, Lapointe L, Hudon C, Vanasse A. Multimorbidity is common to family practice: Is it commonly researched? Can Fam Physician. 2005;51:244–5.
3. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.
4. Fortin M, Hudon C, Hoggerty J, van den Akker M, Almirall J. Prevalence estimates of multimorbidity: a comparative study of two sources. BMC Health Serv Res. 2010;10:111.
5. Perruccio AV, Katz JN, Losina E. Health burden in chronic disease: multimorbidity is associated with self-rated health more than medical comorbidity alone. J Clin Epidemiol. 2012;65(1):100–6.
6. Lehnert T, Heider D, Leicht H, Heinrich S, Corrieri S, Luppa M, et al. Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev. 2011;68:357–75.
7. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. Ann Fam Med. 2012;10(2):142–51.
8. Parekh AK, Goodman RA, Gordon C, Koh HK, HHS Interagency Workgroup. Identification of patients with chronic pain in a primary care setting. J Am Med Inform Assoc. 2013.
9. Salisbury C. Multimorbidity: redesigning health care for people who use it. Lancet. 2012. [Epub ahead of print].
10. Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases—a systematic review on existing multimorbidity indices. J Gerontol A Biol Sci Med Sci. 2011;66(6):301–11.
11. Quan H, Li B, Saunders LD, Parsons GA, Alibhai A, et al. Review: Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a uniquely coded database. Health Serv Res. 2008;43(4):1424–41.
12. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ. 1994;309(6947):125.
13. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, et al. Overview of the Alberta Kidney Disease Network. BMC Nephrol. 2009;10:30.
14. Statistics Canada: Postal Code Conversion File [http://www.statcan.gc.ca; Accessed January 13].
15. Ronksley PE, Tonelli M, Quan H, Manns BJ, James MT, Clement FM, et al. How accurate is ICD coding for multimorbidity in primary health care: creating a research agenda. Preconference Workshop. Vancouver BC: NAPCRG meeting; 2007.
16. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.
17. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(1):1130–9.
18. Tian TY, Zlateva I, Anderson DR. Using electronic health records data to identify patients with chronic pain in a primary care setting. J Am Med Inform Assoc. 2013.
19. Liu L, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(1):1130–9.
20. Marrie RA, Fisk JD, Stadnyk KJ, Yu BN, Tremlett H, Wofson C, et al. The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Can J Neurol Sci. 2013;40(5):624–31.
46. Noyes K, Liu H, Holloway R, Dick AW. Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey. Mov Disord. 2007;22(4):509–14.
47. Fan J, Arruda-Olson AM, Leibson CL, Smith C, Liu G, Bailey KR, et al. Billing code algorithms to identify cases of peripheral artery disease from administrative data. J Am Med Inform Assoc. 2013;20(e2):e349–54.
48. Asgari MM, Wu JJ, Gelfand JM, Salmon C, Curtis JR, Harrold LR, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoeconomics. 2013;22(8):842–9.
49. Lurie N, Popkin M, Dysken M, Moscovice I, Finch M. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Community Psychiatry. 1992;43(1):69–71.
50. Moscovice MF, Lurie N. Minnesota: Plan Choice by the Mentally Ill in Medicaid Prepaid Health Plans. Adv Health Econ Health Serv Res. 1989;10:265–78.
51. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005;36(8):1776–81.